KOL Insight Archives | Report Store

GLP-1 Pulse Survey

This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

August 25, 2014

Find out more

Datamonitor Meningococcal Vaccines KOL Interview

$599.00

Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to determine this physician’s views on marketed and pipeline meningococcal vaccines.

July 12, 2016

Find out more

Wet Age-Related Macular Degeneration (Wet AMD) KOL Interview – Spain

$599.00

A Spain-based KOL opines about the most used agents in wet AMD with particular emphasis on the effect of cost and safety in making prescribing decisions. During the discussion, the KOL gives a glimpse of what the future might hold in terms of newer agents and combination therapy. The KOL also speaks about novel modes of administration and the impact of these on the current market.

September 29, 2022

Find out more

Pulmonary Hypertension KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Adempas, Letairis, Opsumit, Orenitram, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

July 21, 2022

Find out more

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

$599.00

A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.

October 2, 2018

Find out more

Crohn’s Disease KOL Interview – UK

$599.00

This discussion with a UK-based key opinion leader (KOL) includes in-depth opinions on the approved agents and late-stage pipeline drugs in the Crohn’s disease market. In the discussion, the KOL opines in detail about the long-term use of biologics and combinations in Crohn’s disease. The impact of biosimilars and the importance of cost regarding the choice of agents in the treatment of Crohn’s disease are also discussed.

October 13, 2022

Find out more

2015 Breast Cancer Pulse #2

$599.00

This 5-question pulse of 24 oncologists practicing in the United States focuses on the usage of HER2-targeted agents for the treatment of breast cancer.

May 26, 2015

Find out more

Selexipag for Pulmonary Arterial Hypertension

$89.00

Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.

February 1, 2014

Find out more

Ovarian Cancer Pulse Survey

$599.00

Diagnostics/diagnostic techniques discussed:

etarfolatide/folic acid, BRCA mutation testing

May 7, 2014

Find out more

Prostate Cancer KOL Interview – US, Northeast #2

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, Lutetium 177Lu-PSMA-617, and CAN-2409.

February 9, 2022

Find out more

Chronic Neuropathic Pain KOL Survey

$599.00

Biomedtracker performed a 5-question survey of 30 United States neurologists who currently treat patients with chronic neuropathic pain and prescribe opioids to at least some of their patients with chronic neuropathic pain to gauge current use of adjuvants (TCAs, anti-convulsants, SNRIs, SSRIs, and NMDA receptor antagonists) and potential future use of cebranopadol and raxatrigine to treat chronic neuropathic pain.

March 9, 2017

Find out more

Crohn’s Disease KOL Interview – US, Northeast

$599.00

This discussion with a US-based key opinion leader (KOL) includes in-depth opinions on many topics in the Crohn’s disease market. In the discussion, the KOL addresses what the future of the Crohn’s disease market will look like. Also discussed are competition in the market, and how certain factors will lead to one agent triumphing over another. Additionally, the discussion covers the significance of black box warnings, as well as the latest approved agent in Crohn’s disease.

October 13, 2022

Find out more

Drug Pricing and Market Access KOL Interview

$599.00

Expensive oncology treatments [PD-1 and upcoming CAR-T therapies] will continue to be covered by large insurers formularies, but access will be restricted according to NCCN guidelines.

February 1, 2016

Find out more

Schizophrenia and Bipolar Disorder Payer Interview – US, South

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning schizophrenia and bipolar disorder, with a focus on oral antipsychotics and long-acting injectables.

April 28, 2021

Find out more

Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

April 1, 2020

Find out more

Hemophilia KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, BeneFIX, and Eloctate, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.

March 20, 2020

Find out more

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1

$599.00

A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.

October 2, 2018

Find out more

Datamonitor Healthcare Chronic Heart Failure KOL Interview – UK

$599.00

A UK KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

February 4, 2019

Find out more

Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

Find out more

Post-CHDI Huntington’s Disease KOL Interview

$799.00

Indications: Huntington’s Disease, Alzheimer’s Disease Physician Information Specialty: Neurology Location: London, United Kingdom

March 16, 2015

Find out more

2015 Breast Cancer Pulse #1

$599.00

This five-question survey of oncologists focuses on treatments for metastatic or locally advanced, HR+/HER2- breast cancer.

May 13, 2015

Find out more

Ovarian Cancer KOL Interview – US, East Coast

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

April 1, 2020

Find out more

Datamonitor Healthcare Multiple Myeloma KOL Interview – UK

$599.00

This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need.

January 18, 2019

Find out more

Human Papillomavirus (HPV) KOL Interview – US, Midwest

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

January 3, 2020

Find out more

Datamonitor Healthcare Ulcerative Colitis KOL Interviews

$599.00

Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC.

August 18, 2017

Find out more

Datamonitor Healthcare HIV KOL Interview – US #2

$599.00

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Find out more

Crohn’s Disease KOL Interview – US, South

$599.00

This discussion with a US-based key opinion leader (KOL) includes in-depth opinions on the approved agents and late-stage pipeline drugs in the Crohn’s disease market. In the discussion, the KOL opines in detail about the latest approved agents in Crohn’s disease, along with the treatment approach in fistulizing Crohn’s disease. The impact of biosimilars and the importance of cost regarding the choice of agents in the treatment of Crohn’s disease are also discussed.

October 14, 2022

Find out more

Biomedtracker Diabetic Nephropathy/Diabetic Kidney Disease KOL Interview

$599.00

Biomedtracker interviewed a nephrologist based in the US Midwest to determine his views on the drugs in development for diabetic nephropathy/diabetic kidney disease.

May 13, 2016

Find out more

Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy

$599.00

In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Find out more

Chronic Myeloid Leukemia (CML) KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase as well as exploratory mid-phase pipeline therapies for chronic myeloid leukemia. Key pipeline assets highlighted include vodobatinib and Dasynoc.

July 8, 2022

Find out more

Multiple Myeloma KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and UK market access issues are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

May 15, 2020

Find out more

Psychiatry KOL Insight Interview

$599.00

At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)

January 24, 2014

Find out more

Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.

October 21, 2015

Find out more

Abuse-Deterrent Opioids Survey KOL Interview

$599.00

Biomedtracker performed a 5-question survey of 30 United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge current and future use of abuse-deterrent opioids to treat chronic pain.

March 9, 2017

Find out more

Follicular Lymphoma KOL Interview – US

$599.00

This interview with a US-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Future trends and unmet needs are also discussed. Key drug classes highlighted include anti-CD20 antibodies (Rituxan and Gazyva), immunomodulators (Revlimid), autologous CAR-T therapies (Yescarta and Kymriah), CD20 x CD3 bispecifics (Lunsumio), BTK inhibitors (Imbruvica and Brukinsa), EZH2 inhibitors (Tazverik), PI3 kinase inhibitors (Copiktra, Zydelig, Aliqopa, and zandelisib), and anti-CD19 antibodies (Monjuvi).

September 30, 2022

Find out more

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

Find out more

Post-EASL KOL Interview

$599.00

Highlights KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK). Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ). Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens […]

May 29, 2015

Find out more

Colorectal Cancer KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.

May 23, 2022

Find out more

Datamonitor Healthcare HIV KOL Interview – Germany

$599.00

A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Find out more

Rheumatoid Arthritis Payer Interview – Pennsylvania, US

$599.00

A US payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

August 22, 2019

Find out more

Neuromodulation KOL Interview

$599.00

Neuromodulation KOL Interview

February 5, 2015

Find out more

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK

$599.00

An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

November 12, 2018

Find out more

Datamonitor Axial Spondyloarthritis KOL Interviews

$599.00

Datamonitor interviewed three arthritis specialists, one based each in France, Italy and the US, to gauge their views on currently available treatment options, pipeline drugs, biosimilars and treatment challenges in axial spondyloarthritis (axSpA). The three interviews were combined into a single report.

March 9, 2017

Find out more

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US

$599.00

An interview with a US key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine

November 19, 2018

Find out more

Non-Small Cell Lung Cancer KOL Interview – NH, US

$1,099.00

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

August 30, 2018

Find out more